Immatics announces completion of business combination and listing on NASDAQ

Immatics Biotechnologies, the biopharmaceutical company, announced the completion of its business combination with Arya Sciences Acquisition Corp. and will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market.

New investors supporting the transaction include Perceptive Advisors, Redmile Group, Federated Hermes Kaufmann Funds, RTW Investments and Sphera Funds, alongside existing Immatics investors dievini Hopp BioTech, AT Impf and Wellington Partners.

Read more here.

Press enter or esc to cancel